Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth

Proteomic-based drug testing is an emerging approach to establish the clinical value and anti-neoplastic potential of multi-kinase inhibitors. The multikinase inhibitor midostaurin (PKC412) is a promising new agent used to treat patients with advanced systemic mastocytosis (SM). We examined the targ...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Leukemia
Autors principals: Peter, Barbara, Winter, Georg E., Blatt, Katharina, Bennett, Keiryn L., Stefanzl, Gabriele, Rix, Uwe, Eisenwort, Gregor, Hadzijusufovic, Emir, Gridling, Manuela, Dutreix, Catherine, Hoermann, Gregor, Schwaab, Juliana, Radia, Deepti, Roesel, Johannes, Manley, Paul W., Reiter, Andreas, Superti-Furga, Giulio, Valent, Peter
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4896384/
https://ncbi.nlm.nih.gov/pubmed/26349526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.242
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars